Amarin Corp Plc (AMRN)

[sts66]

8-K reveals nothing:

On December 26, 2022, Amarin Corporation plc (the “Company”) entered into a Settlement Agreement (the “Settlement Agreement”) with Health Net, LLC that resolves previously disclosed patent infringement litigation in the U.S. District Court in Delaware. The specific terms of the settlement are confidential. The Company is pleased with the outcome and believes entering into the Settlement Agreement will provide significant value in the market with payors.

The Company will continue to vigorously defend its intellectual property rights related to VASCEPA.

With no idea what settlement terms were (maybe HN has to change it's pre-auth process that allowed CVD patients to get GV), there's no pressure on other insurers to stop illegally providing GV for the R-IT indication - AMRN management screwed up AGAIN. Unbelievable - how much did they spend to get nothing to show for it?

And what's this Amarin's appeal to CAFC from the dismissal with prejudice re Hikma proceeds about? A SA author recently mentioned something about an active appeal but he didn't know the details - what exactly does AMRN have left to appeal? I thought it all ended when the USSC turned AMRN down.